{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:52:01Z","timestamp":1761929521697,"version":"3.38.0"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,12,2]],"date-time":"2010-12-02T00:00:00Z","timestamp":1291248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytometry Part B Clinical"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The involvement of the multidrug resistance (MDR) mediated by ABC transporter proteins P\u2010glycoprotein (Pgp) and multidrug resistance\u2010associated protein\u20101 (MRP1) overexpressions in patients with chronic myeloid leukemia (CML) are not completely understood. Pgp and MRP1 expressions and activity were analyzed in samples from 158 patients with chronic myeloid leukemia (CML). Using flow cytometry, Pgp expression was more frequently observed in early chronic (<jats:italic>P<\/jats:italic>= 0.00) and in advanced (<jats:italic>P<\/jats:italic>= 0.02) CML phases when it was compared to MRP1 expression. Variation of MDR expression and activity were observed during the CML evolution in patients previously treated with interferon and imatinib. In the K562\u2010Lucena cell line, Pgp positive, imatinib caused an enhancing in Pgp expression at protein and mRNA levels, whereas in the Pgp negative cell line, this drug was capable of decreasing<jats:italic>MDR1<\/jats:italic>\/Pgp mRNA levels. Our result emphasizes the importance of understanding the different aspects of MDR status in patients with CML when they are under investigation in determining imatinib resistance. \u00a9 2010 International Clinical Cytometry Society<\/jats:p>","DOI":"10.1002\/cyto.b.20580","type":"journal-article","created":{"date-parts":[[2010,12,2]],"date-time":"2010-12-02T16:12:22Z","timestamp":1291306342000},"page":"158-166","source":"Crossref","is-referenced-by-count":34,"title":["Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients"],"prefix":"10.1002","volume":"80B","author":[{"given":"Flavia C.","family":"Vasconcelos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina L.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma Silva de","family":"Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Felipe R.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Moellmann\u2010Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudete E.","family":"Klumb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel Ciuvalschi","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,2]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.3.3.363"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181a974b3"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<805::AID-CNCR16>3.0.CO;2-E"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-4811-9_52"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02969.x"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(02)00095-9"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V101.6.2368"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0993"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9376-3"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1590\/S0001-37652001000100007"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.07.016"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9453-z"},{"key":"e_1_2_5_15_2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V100.5.1910.h81702001910_1910_1912","article-title":"Cyclosporin inhibition of P\u2010glycoprotein in chronic myeloid leukemia phase","volume":"100","author":"List AF","year":"2002","journal-title":"Blood"},{"key":"e_1_2_5_16_2","first-page":"34","article-title":"P\u2010glycoprotein and multidrug resistance associated protein\u20101 activity in 132 acute myeloid leukemias according to FAB subtypes and cytogenetics risk groups","volume":"8","author":"Legrand O","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403395"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(00)00156-9"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100268"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2009_03_202"},{"key":"e_1_2_5_21_2","first-page":"256","article-title":"Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia","volume":"88","author":"Rosti G","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-103499"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404859"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1134\/S0006297908010045"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0026-895X(25)08713-9","article-title":"Modulators and substrates of P\u2010glycoprotein and cytochrome P4503A coordinately up\u2010regulate these proteins in human colon carcinoma cells","volume":"49","author":"Schuetz EG","year":"1996","journal-title":"Mol Pharmacol"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010173200"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/87912"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528090-00004"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-8-927"}],"container-title":["Cytometry Part B: Clinical Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.b.20580","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.b.20580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T11:24:15Z","timestamp":1740741855000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.b.20580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,2]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1002\/cyto.b.20580"],"URL":"https:\/\/doi.org\/10.1002\/cyto.b.20580","archive":["Portico"],"relation":{},"ISSN":["1552-4949","1552-4957"],"issn-type":[{"type":"print","value":"1552-4949"},{"type":"electronic","value":"1552-4957"}],"subject":[],"published":{"date-parts":[[2010,12,2]]}}}